Loading...
•
Mar 31, 2022
Maravai Q1 2022 Earnings Report
Reported a record-setting first quarter with total revenues reaching $244.3 million, up 65% over the first quarter of 2021.
Key Takeaways
Maravai LifeSciences reported a strong first quarter in 2022, with record quarterly revenue of $244.3 million, representing a 65% increase over the prior year. Net income also saw significant growth, reaching $146.9 million, a 95% increase over the prior year. The company has affirmed its revenue guidance and raised its adjusted EBITDA and adjusted EPS guidance for the full year 2022.
Record quarterly revenue of $244.3 million, an increase of 65% over the prior year.
Nucleic Acid Production base business revenue (excluding COVID-19 related CleanCap® revenue) increased 55% over the prior year.
Net income of $146.9 million for the first quarter, representing growth of 95% over the prior year.
Adjusted EBITDA margins reached a record 77%.
Revenue by Segment
Forward Guidance
Maravai LifeSciences has updated its financial guidance for the full year 2022, projecting total revenue in the range of $920.0 million to $960.0 million, reflecting overall growth of 15% to 20%. Adjusted EBITDA is now expected to be in the range of $650.0 million to $690.0 million, and adjusted fully diluted EPS is expected to be in the range of $1.74 - $1.90 per share.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...